bioMerieux: Management Strategies in Sepsis and Respiratory Infections in the Age of Bio Markers and Rapid Organism Identification
Saturday, October 1
2:30 p.m.– 3:15 p.m.
Location: Expert Theater 2
Dr. Daniel Feinstein, MD
Inappropriate antibiotic administration continues to be an issue in our country and is resulting in continued comorbidity concerns and resistance patterns. Procalcitonin (PCT) is a biomarker that continues to show reduction in inappropriate antibiotic exposure without harm when utilized early in the emergency room in patients with sepsis and lower respiratory tract infections. Appropriate use and success occur when followed in a trend with patient progress in an algorithmic protocol format. In addition to PCT, novel acute infectious disease molecular panels are allowing clinicians to make definitive diagnosis faster. Proper integration of these infectious disease panels with PCT can augment sepsis and respiratory infections decision making. It is this integration that will greatly improve the negative predictive value and a positive predictive value in sepsis and respiratory infections care going forward.